Arcoma AB (Sweden) Performance
| ARCOMA Stock | SEK 10.45 0.20 1.88% |
The firm shows a Beta (market volatility) of 0.49, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Arcoma AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Arcoma AB is expected to be smaller as well. At this point, Arcoma AB has a negative expected return of -0.53%. Please make sure to confirm Arcoma AB's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Arcoma AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Arcoma AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 8.6 M | |
| Total Cashflows From Investing Activities | -4.2 M |
Arcoma |
Arcoma AB Relative Risk vs. Return Landscape
If you would invest 1,525 in Arcoma AB on September 2, 2024 and sell it today you would lose (480.00) from holding Arcoma AB or give up 31.48% of portfolio value over 90 days. Arcoma AB is generating negative expected returns and assumes 2.7928% volatility on return distribution over the 90 days horizon. Simply put, 24% of stocks are less volatile than Arcoma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Arcoma AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcoma AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arcoma AB, and traders can use it to determine the average amount a Arcoma AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.19
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ARCOMA |
Estimated Market Risk
| 2.79 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.53 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arcoma AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arcoma AB by adding Arcoma AB to a well-diversified portfolio.
Arcoma AB Fundamentals Growth
Arcoma Stock prices reflect investors' perceptions of the future prospects and financial health of Arcoma AB, and Arcoma AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcoma Stock performance.
| Return On Equity | 0.0423 | |||
| Return On Asset | 0.0218 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 112.49 M | |||
| Shares Outstanding | 13.05 M | |||
| Price To Earning | 70.28 X | |||
| Price To Book | 2.26 X | |||
| Price To Sales | 0.97 X | |||
| Revenue | 117.13 M | |||
| EBITDA | (2.03 M) | |||
| Cash And Equivalents | 811 K | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 1.81 M | |||
| Debt To Equity | 0.43 % | |||
| Book Value Per Share | 3.48 X | |||
| Cash Flow From Operations | (1.93 M) | |||
| Earnings Per Share | (0.81) X | |||
| Total Asset | 79.27 M | |||
| Retained Earnings | (6 M) | |||
| Current Asset | 47 M | |||
| Current Liabilities | 32 M | |||
About Arcoma AB Performance
By analyzing Arcoma AB's fundamental ratios, stakeholders can gain valuable insights into Arcoma AB's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Arcoma AB has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arcoma AB has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscleskeleton, thoratic, pediatric, and traumaresus clinics. Arcoma AB is traded on Stockholm Stock Exchange in Sweden.Things to note about Arcoma AB performance evaluation
Checking the ongoing alerts about Arcoma AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcoma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcoma AB generated a negative expected return over the last 90 days | |
| The company reported the revenue of 117.13 M. Net Loss for the year was (7.47 M) with profit before overhead, payroll, taxes, and interest of 55.29 M. | |
| Arcoma AB has accumulated about 811 K in cash with (1.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 47.0% of the company shares are held by company insiders |
- Analyzing Arcoma AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcoma AB's stock is overvalued or undervalued compared to its peers.
- Examining Arcoma AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcoma AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcoma AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcoma AB's stock. These opinions can provide insight into Arcoma AB's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Arcoma Stock analysis
When running Arcoma AB's price analysis, check to measure Arcoma AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcoma AB is operating at the current time. Most of Arcoma AB's value examination focuses on studying past and present price action to predict the probability of Arcoma AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcoma AB's price. Additionally, you may evaluate how the addition of Arcoma AB to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |